Gastrointestinal Cancer

SS 38 - GI 4 - Hepato-Pancreatic-Biliary

279 - DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated With Veliparib, Gemcitabine and Radiation Therapy

Wednesday, October 24
11:10 AM - 11:20 AM
Location: Room 206

DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated With Veliparib, Gemcitabine and Radiation Therapy
R. Tuli1, N. N. Nissen2, S. S. Lo3, A. Osipov2, M. Bryant2, M. Tighiouart2, A. E. Hendifar2, and S. L. Shiao4; 1Cedars Sinai Medical Center, Los Angeles, CA, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Cedars-Sinai Medical Center, Los angeles, CA, 4Cedars-Sinai Medical Cne, Los Angeles, CA

Purpose/Objective(s): Locally advanced pancreatic cancer (LA) has a dismal prognosis with current treatment modalities. Preclinical studies have demonstrated radiosensitization of orthotopic pancreatic tumors with the PARP-1/2 inhibitor, veliparib. A phase I trial of veliparib (V), gemcitabine (G) and radiation therapy (RT) was conducted to determine the maximum tolerated dose (MTD), safety and clinical activity of this regimen in patients with LA with and without DNA damage repair (DDR) defects.

Materials/Methods: LA patients were treated with weekly G (1000 mg/m2), daily RT (36 Gy/15 fractions) and daily V 20 mg BID for 3 weeks escalated per a novel Bayesian method followed by standard chemotherapy. DAVID was used to interpret differential gene expression. Cox regression model was used to identify DDR pathways associated with survival. Next generation sequencing (NGS) identified genetic mutations involved in DDR, tumor mutation burden (TMB) and microsatellite instability (MSI) status. Blood samples were interrogated for PAR protein and cytokines using an ELISA and electrochemiluminescent array, respectively. The log-rank test was used to evaluate differences in PFS and OS.

Results: 34 patients were enrolled from 2013 to 2016. MTD of veliparib was 40 mg BID with gemcitabine 400 mg/m2 and RT (36 Gy/15). 12 patients experienced DLT (83.3% lymphopenia, 8.3% neutropenia). Median PFS and OS were 10 and 15 months, respectively. Gene expression analysis identified DDR defects in 50% of patients. Median PFS and OS were significantly higher for these biomarker positive patients (17 vs. 8 mos, p<.01; 22 vs. 12 mos, p<.001, respectively). NGS identified 10 DDR mutations which were not prognostic of outcome. median TMB was 1.8 mut/Mb. A single MSI high patient was identified who was also TMB high (>20 mut/MB) and harbored DDR deficiency by NGS. Lower PAR levels were associated with borderline statistically significant improvements in both PFS and OS (p<.06). Higher levels of IL2 and IL12 and lower levels of FLT1 were associated with improved PFS and OS (p<.05).

Conclusion: The combination of V, G and RT was well tolerated. DDR alterations were identified in a large proportion of patients and were associated with significantly improved PFS and OS. Whereas most patients were MSS and had low TMB, those with higher levels of pro-inflammatory cytokines were likely to harbor DDR alterations both of which were associated with improved outcomes.

Author Disclosure: R. Tuli: None. N.N. Nissen: None. A. Osipov: None. M. Tighiouart: None. S.L. Shiao: Employee; Cedars-Sinai Medical Center. Research Grant; ASTRO, UCLA CTSI, NCI, DoD. Member and Liaison to CNS Group; NRG Oncology. Member; NCI Immunomodulation and Radiation Working Group.

Richard Tuli, MD, PhD

Disclosure:
Employment
Cedars-Sinai Medical Center: Associate Professor: Employee

Presentation(s):

Send Email for Richard Tuli


Assets

279 - DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated With Veliparib, Gemcitabine and Radiation Therapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for DNA Repair Deficiency, Genomic Instability and Immune Profiling in a Phase 1 Study of Locally Advanced Pancreatic Cancer Patients Treated With Veliparib, Gemcitabine and Radiation Therapy